The company's next-generation sequencing-based test is used to aid the detection of cancers in patients with indeterminate lesions.

Oncologists were one of the few provider groups to register support for the FDA rule, reflecting the challenge of assessing ...

The companies have partnered with the goal of streamlining point-of-care access to Guardant's genomic cancer test portfolio.